Do You Qualify for Psychedelic Therapy? How to Know

Do You Qualify for Psychedelic Therapy? The Short Answer

You may qualify for psychedelic therapy if you are an adult experiencing moderate to severe symptoms of depression, anxiety, or PTSD.^1,5 Rather than serving as a last resort, these treatments are increasingly utilized as an evidence-based next step when standard interventions have not provided sufficient relief.³ A licensed prescriber determines your eligibility through a comprehensive intake screening.

Your medical eligibility is evaluated across three primary areas to ensure the treatment is safe and appropriate for your unique needs. These factors include:

• Health history: Providers evaluate cardiovascular health, history of seizure disorders, and pregnancy status to rule out potential physiological risks.
• Current medications: Certain medications, such as SSRIs or MAOIs, may require careful review or tapering under prescriber supervision before starting treatment.⁴
• The specific substance: Ketamine is federally legal and widely accessible today, whereas psilocybin and MDMA remain restricted to research trials or specific state-regulated programs.

Ultimately, a licensed prescriber must review your health history during a formal intake screening to confirm your eligibility.

What Is Psychedelic Therapy?

Psychedelic therapy combines specific psychoactive compounds with a care-guided therapeutic framework to address the root causes of mental health conditions. It is not the substance alone that produces lasting change, but rather the medicine delivered within a protocol-driven therapeutic framework. This approach ensures that the psychological experience is supported by trained professionals at every stage.

The framework has three fixed parts: preparation, a supervised dosing session, and integration. Remove any one of them and what remains is not psychedelic therapy.

As noted earlier, the dosing schedule is finite rather than daily. What matters for the mechanism is timing: the neuroplastic window opens within hours and stays open for days, which is when integration work does the most. Most people find the dissociative state therapeutically meaningful within a supervised setting, as it helps the brain form new connections and shift away from rigid, negative thought patterns.

What Conditions Can Psychedelic Therapy Help Treat?

Peer-reviewed research suggests that certain psychedelic-assisted treatments can reduce symptoms across several common mental health conditions, although the strength of evidence and clinical appropriateness vary by substance and indication. These conditions are common, widely experienced mental health challenges rather than rare or extreme diagnoses. The treatment approach focuses on addressing the root causes of these symptoms rather than temporarily suppressing them.

The primary conditions addressed by this modality include:

• Depression: Psychedelic treatments temporarily modulate neural communication to rapidly reduce depressive symptoms and build long-term emotional resilience.¹
• Anxiety disorders: The treatment helps quiet overactive brain networks, allowing individuals to reframe physiological anxiety responses and chronic worry.¹
• PTSD: By opening a neuroplastic window, these therapies help individuals process traumatic memories and rebuild a sense of safety.⁵

Beyond these primary indications, investigators are actively expanding into other areas of mental and behavioral health. These include obsessive-compulsive disorder, substance use disorders, chronic pain, prolonged grief, and burnout. While the strength of the evidence varies by indication, a licensed physician will evaluate your specific symptoms to determine whether the protocol fits.

What Types of Psychedelic Therapy Exist?

Several distinct substances are utilized within guided psychedelic therapy, but they differ significantly in their legal availability, delivery settings, and evidence bases. Those differences determine whether a given option is available to you this month or several years from now.

Ketamine Therapy

Ketamine is a legal, FDA-approved anesthetic that has been prescribed off-label by licensed providers for mental health conditions for decades.³ Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the World Health Organization List of Essential Medicines since 1985.¹⁰ Five decades of bedside use establish it as a well-understood medicine rather than an experimental compound. Off-label prescribing is a standard, widespread practice in U.S. medicine, representing approximately 21% of all prescriptions.⁹ This treatment is administered in two primary contexts, which are in-clinic intravenous infusions and at-home programs, such as Mindbloom, using sublingual tablets or subcutaneous injections.

Spravato, which is a patented esketamine nasal spray, is also FDA-approved for treatment-resistant depression but must be administered in a certified clinic under strict monitoring requirements.¹¹ At-home ketamine, IV ketamine, and Spravato differ in administration route, setting, monitoring, regulatory status, and cost; direct comparisons should be interpreted cautiously because studies use different designs, patient populations, and outcome measures. The table below outlines the primary differences between these delivery methods:

Ketamine is the only psychedelic therapy modality available today without trial enrollment, international travel, or state-specific restrictions. For someone who wants supervised treatment to begin within weeks rather than years, that access gap is decisive.

Psilocybin Therapy

Psilocybin is a naturally occurring compound found in certain species of mushrooms that is currently being studied for depression, anxiety, and addiction.³ Under federal law, psilocybin remains classified as a Schedule I controlled substance, meaning it has no recognized medical use at the federal level. While Oregon and Colorado have established state-regulated access programs with licensed facilitators, these programs operate outside the traditional medical system and are geographically limited.

Trials at major research institutions continue to generate high-quality evidence supporting its therapeutic potential. However, psilocybin therapy is not yet broadly available as a standard medical treatment. Qualifying for this modality currently requires either residing in a state with a regulated program or enrolling in an active research trial.

MDMA Therapy

MDMA-assisted therapy has been studied extensively as a treatment for post-traumatic stress disorder, showing high rates of symptom reduction in Phase 3 trials.⁸ In 2024, the FDA declined to approve MDMA-assisted therapy, citing the need for additional research regarding trial methodology. Consequently, MDMA remains classified as a Schedule I controlled substance with no approved medical use.

Researchers are continuing to run additional trials to address the regulatory requirements for future approval. At present, MDMA therapy is not available to the public outside of these research settings. Individuals interested in this modality must locate and qualify for enrollment in an active study.

Is Psychedelic Therapy Legal in the United States?

The legal status of psychedelic treatments in the United States depends on the specific substance, federal regulations, and state-level legislation. Ketamine is currently the only psychedelic therapy modality that is federally legal and available nationwide through licensed providers. Other substances, such as psilocybin and MDMA, remain federally illegal but are navigating evolving regulatory pathways.

At the federal level, regulatory agencies are actively working to accelerate research into these treatments. In April 2026, the White House issued an executive order titled 'Accelerating Medical Treatments for Serious Mental Illness,' directing the FDA to prioritize review of psychedelic drugs that have received Breakthrough Therapy designation, and directing HHS and the FDA to collaborate with the Department of Veterans Affairs to expand trial access and evidence-gathering. The order accelerates research and review pathways; it does not itself approve any psychedelic drug for therapeutic use. The FDA has granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression and to MDMA for PTSD, which expedites the review process but does not constitute approval.

State-level regulations are also shifting across the country. Oregon's regulated psilocybin services program launched in 2023, and Colorado's program is currently in development. Several other states have introduced bills to study or regulate psychedelic therapy access, reflecting a growing interest in these treatments.

Ketamine remains legal nationwide as a Schedule III controlled substance. It is prescribed off-label by licensed providers for mental health conditions and is available through both in-clinic and at-home programs. Legality and access are the same problem in practice. Ketamine is the only modality where legal status, care infrastructure, and published evidence line up today, which is why eligibility questions almost always resolve there.

What Does Research Say About Psychedelic Therapy for Mental Health?

Modern psychedelic research dates back to the 1950s, was temporarily paused due to regulatory shifts, and has returned to rigorous scientific investigation over the past two decades. Major academic institutions, including Johns Hopkins and NYU, have established dedicated research centers to study these compounds. This deep and expanding evidence base has shifted psychiatric consensus toward recognizing these therapies as legitimate treatment tools.³

A substantial and well-established body of peer-reviewed research demonstrates the therapeutic efficacy of psychedelic medicines across multiple conditions. This evidence base spans decades of study at leading academic institutions and highlights the potential for rapid, long-lasting symptom reduction.

Key findings by modality include:

• Psilocybin for depression: Research from Johns Hopkins demonstrated that psilocybin-assisted therapy produced rapid and sustained reductions in depressive symptoms, with effects persisting for weeks to months after treatment.³
• MDMA for PTSD: Phase 3 trials showed that MDMA-assisted therapy produced clinically and statistically significant reductions in PTSD symptoms compared to therapy with placebo.⁸
• Ketamine for depression, anxiety, and PTSD: A substantial body of peer-reviewed research supports ketamine's efficacy across multiple conditions. Building on decades of psychiatric research, Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy to date in the Journal of Affective Disorders (Hull et al., 2022; Mathai et al., 2024), conducted on Mindbloom clients using the Mindbloom treatment protocol. Key findings include: 89% of clients reported symptom improvement for anxiety and depression, with response rates of 56.4% for depression and 56.1% for anxiety.^1,2 For PTSD, a peer-reviewed study by Parks et al. (2026) in the Journal of Medical Internet Research found a 92% symptom improvement rate, with a 76.7% response rate and 56.7% remission rate⁵

Research supports potential therapeutic benefit across multiple conditions in appropriately screened patients, with the evidence base and regulatory status varying by modality and indication. The more relevant question for someone evaluating eligibility is which modality has the access, evidence, and supervised infrastructure to support their care today.

How Is Psychedelic Therapy Conducted?

Supervised psychedelic treatments follow a standardized care sequence built around patient safety and therapeutic efficacy. Each stage builds on the one before it, so the dosing session never occurs in isolation from screening or integration.

The standard sequence includes:

1. Initial consultation and screening: A licensed physician reviews health history, current medications, mental health diagnoses, and care goals to determine eligibility.
2. Treatment planning: If eligible, the provider develops a personalized care plan including substance, dosing protocol, and session structure.
3. Preparation: Education about what to expect, intention-setting, and logistical planning, including ensuring a peer treatment monitor is present for at-home sessions.
4. Dosing session: Administration of the compound in the appropriate in-office or home setting with monitoring.
5. Integration: Clinician-supervised post-session support to process the experience and translate insights into lasting change.

The specific details vary by modality and provider. In-clinic psilocybin sessions in Oregon involve licensed facilitators and extended observation periods. IV ketamine is administered on-site at an infusion clinic under direct in-person monitoring. At-home ketamine programs deliver dosing in the client's own environment with remote prescriber oversight and a required peer treatment monitor present.

Regardless of modality, the consistent safeguards are screening, supervised administration, and integration. These are what distinguish therapeutic use from unsupported use.

What Factors Can Disqualify Someone From Psychedelic Therapy?

Eligibility is determined through a comprehensive screening process in which a licensed physician weighs both physical and psychological safety factors. Some conditions represent clear contraindications; others require medical judgment and may involve medication adjustments before treatment can begin.

Medical and Psychiatric Contraindications

Contraindications are physical or psychiatric conditions that may make psychedelic therapy inappropriate due to safety concerns. These factors are evaluated during your initial screening to protect your health.

Specific contraindications include:

• Uncontrolled hypertension: Ketamine can temporarily increase blood pressure. Individuals with uncontrolled hypertension may not be appropriate candidates, which is why cardiovascular screening is part of the intake process.
• Serious cardiovascular disease: Conditions involving significant cardiac risk, such as congestive heart failure, require careful evaluation.
• Seizure disorders: Some psychedelic compounds may lower the seizure threshold, making active epilepsy a key consideration.
• Pregnancy: Psychedelic therapy is not administered during pregnancy or while nursing.
• Current medications requiring tapering: SSRIs, MAOIs, and certain other medications may need to be tapered under supervision before beginning ketamine sessions. Tapering is managed by your prescribing physician, not a self-directed decision.

Having one of these conditions does not necessarily mean permanent disqualification. It means a treating specialist needs to evaluate whether dosing can proceed safely, potentially after medication adjustments or cardiovascular stabilization.

Does a Bipolar or Schizophrenia Diagnosis Disqualify You?

Bipolar disorder and schizophrenia spectrum disorders are frequently cited as contraindications for psychedelic therapy. Psychedelic compounds can induce altered states of consciousness that may precipitate manic episodes in individuals with bipolar disorder or exacerbate psychotic symptoms in individuals with schizophrenia spectrum conditions. The concern is not theoretical; it rests on documented case observation and is reflected in the exclusion criteria of most trials and dosing protocols.

Bipolar disorder and schizophrenia spectrum conditions require careful individualized assessment by a licensed physician, and many protocols may determine that psychedelic therapy is not appropriate. If you have either diagnosis, disclose it during your intake evaluation.

Age and Other Screening Considerations

Beyond specific medical diagnoses, providers evaluate additional factors during screening. If any of these factors would make full participation unsafe or impractical, screening is where that surfaces.

Key screening considerations include:

• Age: Most psychedelic therapy programs require clients to be 18 or older. Some programs have upper age considerations that factor in cardiovascular health and medication burden.
• Substance use history: Active substance use disorders may need to be addressed before beginning psychedelic therapy. A history of substance use does not automatically disqualify someone, but it is part of the intake evaluation.
• Cognitive capacity: The ability to provide informed consent and engage in the therapeutic process (preparation, session participation, integration) is a practical requirement.

Screening is comprehensive because safety depends on it. A thorough evaluation protects the client and gives the protocol its best chance of producing durable outcomes.

How Mindbloom's Care Protocol Supports Safe, Effective Treatment

Mindbloom delivers a comprehensive, at-home ketamine therapy program designed around rigorous safety protocols and guided therapeutic support. What makes responsible at-home ketamine therapy work is the combination of rigorous screening, provider oversight, guided integration, and ongoing monitoring.

The care model structure includes:

• Prescriber consults: The screening described above is conducted by Mindbloom's licensed physicians, who also set your dose, cadence, and session count.
• Guide coaching sessions: One-on-one sessions for preparation before and integration after each ketamine treatment.
• Unlimited Group Integration Circles: Peer-supported integration in a facilitated community setting.
• Peer treatment monitor: Required for every at-home session, as outlined above. Mindbloom reviews your chosen monitor during intake and provides them written instructions before your first dose.
• Mindbloom App and Bloombox: Guided programs with custom soundscapes and a physical toolkit to optimize set and setting.

Building on decades of medical research, Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy to date in the Journal of Affective Disorders.^1,2 These studies were conducted on Mindbloom clients using the Mindbloom protocol. Outcomes from these programs are cited above. On safety specifically, side effects occur in approximately 4% to 5% of sessions and serious adverse events in fewer than 0.1%.^1,2

Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, a licensed physician conducts a comprehensive evaluation to confirm your eligibility and personalize your care plan. Mindbloom's at-home ketamine therapy starts at $165 per guided session for an 18-session program, billed as $330 monthly over 9 months, with a total cost of $2,970. Shorter programs are also available, including a 12-session program at $185 per session (billed as $370 monthly over 6 months, totaling $2,220) and a 6-session program at $215 per session (billed as $430 monthly over 3 months, totaling $1,290). Continuing clients benefit from a streamlined experience and preferred pricing, starting at $129 per session for an 18-session program.

Mindbloom is the only at-home ketamine provider offering subcutaneous administration (Injectables) in addition to sublingual tablets, which allows dosing to be matched to a client's response profile.

What Are the Next Steps If You Think You Qualify?

Taking the first step toward psychedelic therapy involves preparing your health history and scheduling a professional evaluation. If you are an adult experiencing depression, anxiety, PTSD, or a related condition, you may be a candidate. The way to find out is through a professional evaluation, not self-diagnosis.

Actionable next steps include:

1. Review your current medications: Speak with your prescribing provider to identify any medications that may require tapering.
2. Gather your health history: Compile your past diagnoses, previous treatments, and current health conditions.
3. Schedule an initial screening: Connect with a licensed specialist in psychedelic-assisted treatments to evaluate your eligibility.

Ketamine therapy is legally available today and does not require trial enrollment. If you are ready to find out whether you qualify, the first step is a medical evaluation. Mindbloom's at-home model is approximately 60% more affordable per session than IV ketamine clinics. Clients may be eligible to reimburse a portion of their program cost through major insurance providers or use HSA/FSA dollars.

Book My Breakthrough

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.